Methods and materials for assessing prostate cancer therapies

US8034548B2 · kind B2 · utility

Assignee

• The Regents of the University of California · US

Inventors

• Charles L. Sawyers · New York, US
• Charlie D. Chen · Los Angeles, US
• Derek Welsbie · Rancho Santa Fe, US

Key dates

• Filing date: Dec 16, 2004
• Grant date: Oct 11, 2011
• Expiry date: Jan 4, 2027

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2500/04
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

Using microarray-based profiling of isogenic prostate cancer xenograft models, we found that a modest (2-5 fold) increase in androgen receptor (AR) mRNA was the only expression change consistently associated with developing resistance to antiandrogen therapy. Increased levels of AR confer resistance to anti-androgens by amplifying signal output from low levels of residual ligand and altering the normal response to antagonists. This invention provides cell based assays for use in the examination of new therapeutic modalities and provides insight toward the design of novel antiandrogens.